Drugs / IZELTABART TAPATANSINE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | 2020-07-30 | “Received acceptance for an investigational new drug (IND) application for IMGC936, a novel ADAM9-targeting ADC being co-developed with MacroGenics, from the US Food and Drug...” abbvie.com ↗ “In July, MacroGenics received FDA clearance of the Investigational New Drug (IND) application for IMGC936” macrogenics.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04622774 | Oct 2020 → Dec 2023 | — | ImmunoGen, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-04-10 | AbbVie | Results ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting abbvie.com ↗
IMGC936 showed compelling anti-tumor activity against multiple patient-derived xenograft models with clinically relevant levels of ADAM9 and was well-tolerated across all models tested. |
| 2021-04-10 | MacroGenics | Results MacroGenics Announces Presentations at the 2021 AACR Annual Meeting macrogenics.com ↗
Finally, our third poster highlights pre-clinical data on IMGC936 , an investigational ADAM9-directed ADC being developed in collaboration with ImmunoGen Inc. |
| 2019-04-03 | MacroGenics | Results MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019 macrogenics.com ↗
Preclinical data presented at AACR showed activity of IMGC936 in vitro and in xenograft models of human tumors expressing ADAM9: |
| 2019-02-27 | AbbVie | Results ImmunoGen Announces Multiple Presentations at AACR Annual Meeting abbvie.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-10 | AbbVie | ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting abbvie.com ↗ |
| 2021-04-10 | MacroGenics | MacroGenics Announces Presentations at the 2021 AACR Annual Meeting macrogenics.com ↗ |
| 2019-04-03 | MacroGenics | MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019 macrogenics.com ↗ |
| 2019-02-27 | AbbVie | ImmunoGen Announces Multiple Presentations at AACR Annual Meeting abbvie.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IZELTABART TAPATANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095346 ↗ |
| Known as | IMGC936 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622774 ↗ |
| Route | Intravenous | “IMGC936 administered by intravenous (IV) infusion” NCT04622774 ↗ |
| Target | ADAM9 | “IMGC936, a novel ADC targeted against ADAM9.” PMID 35511740 ↗ Jul 2022 |